News

April 15, 2020April 15, 2020

Antibody-drug Conjugate XMT-1536 Shows Promise for Ovarian Cancer in Phase 1 Trial

News

Treatment with XMT-1536 appears to be safe, with promising responses shown in heavily pretreated patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma in a Phase 1 clinical ... Read more

April 8, 2020April 8, 2020

Partnership to Ensure Gene-modified Cell Therapies for Ovarian Cancer Trials

News

Senti Biosciences is working with RoosterBio to ensure a quality supply of its candidate gene-modified cell therapies for ovarian cancer and other solid tumors, with a goal of bringing them into clinical ... Read more

April 1, 2020April 1, 2020

Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending

News

Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of the study’s ... Read more

March 25, 2020March 25, 2020

GEN-1 Added to Chemo Improves Removal of Ovarian Tumors, Early Data Show

News

The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian cancer, according to initial results of the OVATION 2 study. Adding GEN-1 to neoadjuvant chemotherapy ... Read more

March 23, 2020March 23, 2020

Cellular Recycling Genes Linked to Ovarian Tumor Formation in Mice, Study Shows

News

Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes the formation of ovarian cancer tumors, a study in ... Read more

March 20, 2020March 20, 2020

China Reviewing Zejula as First-line Therapy for Ovarian Cancer

News

The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) be approved as first-line maintenance therapy for women with ovarian cancer who are responding to ... Read more

March 18, 2020March 18, 2020

NCCN, AstraZeneca Projects Target Advanced Ovarian Cancer Patients

News

Four projects chosen by the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program will explore ways to use technology to improve care for advanced ovarian cancer patients. Funded by AstraZeneca, ... Read more

March 16, 2020March 23, 2020

Cediranib-Lynparza Combo Fails to Delay Disease Progression in Relapsed Ovarian Cancer

News

A combination of the investigational therapy cediranib and Lynparza (olaparib) fails to delay disease progression in women with platinum-sensitive relapsed ovarian cancer compared with standard platinum-based chemotherapy, findings from a Phase ... Read more

March 13, 2020March 23, 2020

CytoDyn Cleared to Start Phase 2 Basket Trial of Leronlimab for Multiple Solid Cancers

News

CytoDyn has been cleared by an institutional review board to start a Phase 2 trial testing its investigational therapy leronlimab (PRO 140) to treat about 22 different solid cancers, including ovarian ... Read more

March 11, 2020March 11, 2020

‘Cycle for Survival’ Fundraiser Surpasses $250 Million Milestone

News

Including donations from more than 1 million individuals across all 50 states, 13-year-old Cycle for Survival has raised more than $250 million to date to fight rare malignancies such as ... Read more